JohnKWaasDO

PubMed

• A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Ea...
  Wang, H., Shaverdashvili, K., Reyes, V., Mehta, D., Marsh, C., Waas, J., VanderWeele, R., Peracha, S., Liang, H., Socinski, M., Gerber, D., Dowell, J., Villaruz, L.> ;Eclinicalmedicine. 2023 Dec 1
• 106 citations
  Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results o...
  Suzanne Lentzsch, Amy K. O’Sullivan, Ryan Kennedy, Mohammad Abbas, Lijun Dai, Silvana Pregja, Steve Burt, Michael Boyiadzis, G. David Roodman, Markus Y. Mapara, Mounze...> ;Blood. 2011 Nov 18
• 33 citations
  Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416
  Afshin Dowlati, Kelly Robertson, Tomas Radivoyevitch, John Waas, Nicholas P. Ziats, Paul Hartman, Fadi W. Abdul-Karim, Jay Wasman, Jack Jesberger, Jonathan S. Lewin, K...> ;Clinical Cancer Research. 2005 Nov 1
• 13 citations
  Successful management of life-threatening hemorrhage in a patient with synchronous lupus anticoagulant and factor VIII inhibitor.
  Hans A. Brings, John Waas, Keith R. McCrae, Henry Baele, Jerry Goldstone> ;Journal of Vascular Surgery. 2002 Oct 1
• 321 citations
  A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients ...
  Afshin Dowlati, Kelly Robertson, Matthew M. Cooney, William P. Petros, Michael Stratford, John A. Jesberger, Niusha Rafie, Beth Overmoyer, Vinit Makkar, Bruce S. Stamb...> ;Cancer Research. 2002 Jun 15
• Join now to see all